Immunovant (IMVT) Operating Leases (2020 - 2024)

Immunovant (IMVT) has 5 years of Operating Leases data on file, last reported at $138000.0 in Q1 2024.

• Quarterly Operating Leases rose 193.62% year-over-year to $138000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $138000.0 (up 193.62% YoY) and the FY2024 annual result came in at $138000.0, up 193.62% from the prior year.
• Operating Leases improved to $138000.0 in Q1 2024, from $47000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $4.2 million in Q2 2020 to a low of $47000.0 in Q1 2023.
• A 5-year average of $1.6 million and a median of $1.7 million in 2021 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases tumbled 96.14% — and 2024, when it jumped 193.62%.
• Tracing IMVT's Operating Leases over 5 years: stood at $2.4 million in 2020, then slipped by 29.77% to $1.7 million in 2021, then tumbled by 81.79% to $306000.0 in 2022, then sank by 84.64% to $47000.0 in 2023, then jumped by 193.62% to $138000.0 in 2024.
• The last three Operating Leases figures came in at $138000.0 (Q1 2024), $47000.0 (Q1 2023), and $306000.0 (Q4 2022), per Business Quant data.